Glen Clack
Managing Director @Ailse Oncology Ltd
Signup · Get unlimited contacts
WORK HISTORY
Managing Director @Ailse Oncology Ltd
Macclesfield, GB
Ailse Oncology Ltd. is a specialist consultancy providing the following services in the areas of clinical haematology/oncology to the pharmaceutical/biotechnology industry and academia- Translational/experimental cancer medicine strategy between \'lead optimisation\' and clinical \'proof of concept\'- Strategic clinical development plans - Protocol development (phase I-IV)- Interaction with regulatory agencies on behalf of client companies - Pharmacovigilence- Medical monitoring support- Participation in advisory boards/safety review committees- Key Opinion Leader developmentAilse Oncology Ltd has clinical development expertise across a wide range of solid tumours and haematological malignancies and currently works with clinical research organizations, oncology biotech companies, medical charities and academia.
EDUCATION
University of Wales, Cardiff
Diploma in Pharmacutical Medicine, Pharmaceutical Medicine
Faculty of Medicine, The University of Sheffield
Doctor of Medicine (MD), Section of Human Metabolism, Division of Clinical Sciences
The Royal Free Hospital School of Medicine, the University of London
Bachelor of Medicine (MB) Bachelor of Surgery (BS), Medicine
Faculty of Pharmaceutical Medicine, The Royal College of Physicians
Fellow of the Faculty of Pharmaceutical Medicine, Pharmaceutical Medicine
Christian Medical College Hospital, Vellore, Tamil Nadu, India
Elective Student, Surgery
Faculty of Pharmaceutical Medicine, Royal College of Physicians
Member of the Faculty of Pharmaceutical Medicine, Pharmaceutical Medicine
SKILLS
ABOUT GLEN CLACK
Accomplished senior leader and governance professional with extensive experience providing strategic direction and board oversight to biopharmaceutical and life sciences organisations. Demonstrates deep expertise in oncology innovation, clinical development strategy, regulatory frameworks, and emerging technologies. Proven track record of adding substantial value to boards through independent scientific judgment, risk assessment, and strategic guidance. Highly effective at translating complex scientific and regulatory landscapes into actionable board-level insights. Extensive global network across industry, academia, and regulatory authorities.Key Value Propositions- Strategic oversight of clinical development programs and regulatory pathways- Independent scientific judgment on emerging therapeutic approaches and biomarker strategies- Risk identification and mitigation in oncology and translational medicine- Governance expertise in regulated life sciences environments- Network access to key opinion leaders, regulators, and institutional partners- Coaching and mentorship of executive leadership teams
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.